Rudenko A V, Maĭdannik V G, Drannik G N, Romanenko A M, Bavina E N, Dem'ianova T V
Urol Nefrol (Mosk). 1993 May-Jun(3):13-6.
Fibronectin levels were measured by enzyme immunoassay in 68 patients with pyelonephritis and 10 patients with chronic cystitis. The patients with chronic cystitis, acute and chronic non-obstructive pyelonephritis exhibited significantly high average blood fibronectin levels, whereas those with chronic obstructive pyelonephritis displayed the levels slightly different from those observed in healthy individuals. Hypofibronectinemia was detected in 23.3% of patients with chronic pyelonephritis. Preincubation of the neutrophils isolated from pyelonephritis patients with fibronectin increased the initially low phagocytic capacity without enhancing their metabolic activity. In experimental pyelonephritis, administration of exogenous fibronectin was demonstrated to contribute to a rapid bacterial elimination from the kidneys, to decrease the intensity of an inflammatory response, to prevent renal histostructural lesions, to enhance the functional activity of immunocompetent cells and to stabilize their membranes. The findings may serve the basis for using fibronectin in clinical practice as a promising agent to treat pyelonephritis.
采用酶免疫分析法对68例肾盂肾炎患者和10例慢性膀胱炎患者进行纤连蛋白水平检测。慢性膀胱炎、急慢性非梗阻性肾盂肾炎患者的平均血纤连蛋白水平显著升高，而慢性梗阻性肾盂肾炎患者的水平与健康个体略有不同。23.3%的慢性肾盂肾炎患者检测到纤连蛋白血症。用纤连蛋白预孵育从肾盂肾炎患者分离的中性粒细胞，可提高最初较低的吞噬能力，而不增强其代谢活性。在实验性肾盂肾炎中，外源性纤连蛋白的给药被证明有助于从肾脏快速清除细菌，降低炎症反应强度，预防肾脏组织结构损伤，增强免疫活性细胞的功能活性并稳定其细胞膜。这些发现可为纤连蛋白在临床实践中作为治疗肾盂肾炎的有前景药物提供依据。
